{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:32:05Z","timestamp":1793280725641,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40263-026-01335-3","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:19:04Z","timestamp":1790767144000},"page":"1547-1559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7260-8131","authenticated-orcid":false,"given":"Aisling","family":"McGuigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah A.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"1","key":"1335_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1335_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40263-023-01059-8","volume":"38","author":"S Crisafulli","year":"2024","unstructured":"Crisafulli S, Boccanegra B, Carollo M, et al. Myasthenia gravis treatment: from old drugs to innovative therapies with a glimpse into the future. CNS Drugs. 2024;38(1):15\u201332.","journal-title":"CNS Drugs"},{"issue":"1","key":"1335_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1(1):16\u201322.","journal-title":"Neurohospitalist"},{"issue":"11","key":"1335_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, et al. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235.","journal-title":"J Clin Med"},{"issue":"4","key":"1335_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"5","key":"1335_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/1750743X.2025.2491295","volume":"17","author":"A Matic","year":"2025","unstructured":"Matic A, Bril V. Rozanolixizumab for myasthenia gravis: a breakthrough treatment and future prospects. Immunotherapy. 2025;17(5):309\u201316.","journal-title":"Immunotherapy"},{"issue":"6","key":"1335_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40263-024-01090-3","volume":"38","author":"N Alfaidi","year":"2024","unstructured":"Alfaidi N, Karmastaji S, Matic A, et al. FcRn inhibitor therapies in neurologic diseases. CNS Drugs. 2024;38(6):425\u201341.","journal-title":"CNS Drugs"},{"issue":"7","key":"1335_CR8","first-page":"1111","volume":"10","author":"B Smith","year":"2018","unstructured":"Smith B, Kiessling A, Lledo-Garcia R, et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs. 2018;10(7):1111\u201330.","journal-title":"MAbs"},{"issue":"14","key":"1335_CR9","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s40265-023-01933-1","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Rozanolixizumab: first approval. Drugs. 2023;83(14):1341\u20137.","journal-title":"Drugs"},{"issue":"6","key":"1335_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40267-024-01077-6","volume":"40","author":"SM Hoy","year":"2024","unstructured":"Hoy SM. Rozanolixizumab in generalized myasthenia gravis: a profile of its use. Drugs Ther Perspect. 2024;40(6):203\u201310.","journal-title":"Drugs Ther Perspect."},{"key":"1335_CR11","unstructured":"US Food & Drug Administration. RYSTIGGO\u00ae (rozanolixizumab-noli) injection, for subcutaneous use: US prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761286Orig1s000TOC.html. Accessed 25 Aug 2026."},{"key":"1335_CR12","unstructured":"UCB Canada Inc. RYSTIGGO\u00ae rozanolixizumab injection solution 140 mg\/mL, subcutaneous use: Canadian product monograph. 2025. https:\/\/www.ucbcanada.com\/en\/our-medicines. Accessed 25 Aug 2026."},{"key":"1335_CR13","unstructured":"UCB Japan Inc. RYSTIGGO\u00ae (rozanolixizumab): Japanese prescribing information. 2023. https:\/\/hcp.ucbcares.jp\/product\/rystiggo\/sc420mg#. Accessed 25 Aug 2026."},{"key":"1335_CR14","unstructured":"European Medicines Agency. Rystiggo 140 mg\/ml solution for injection: EU summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rystiggo. Accessed 25 Aug 2026."},{"key":"1335_CR15","unstructured":"UCB Inc. RYSTIGGO\u00ae (rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods [media release]. 31 Jan 2025. https:\/\/www.ucb.com\/newsroom\/."},{"key":"1335_CR16","unstructured":"UCB Inc. RYSTIGGO\u00ae (rozanolixizumab) receives approval in Japan for two new administration methods as UCB begins ONWARD program for patient support [media release]. 9 May 2025. https:\/\/www.ucb.com\/newsroom\/."},{"issue":"10","key":"1335_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-025-13420-6","volume":"272","author":"V Bril","year":"2025","unstructured":"Bril V, Antozzi C, Berkowicz T, et al. Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study. J Neurol. 2025;272(10):1\u201312.","journal-title":"J Neurol"},{"issue":"2","key":"1335_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/22143602241308181","volume":"12","author":"AA Habib","year":"2025","unstructured":"Habib AA, Dru\u017cd\u017c A, Grosskreutz J, et al. Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: results from the phase 3 MycarinG study and an open-label extension. J Neuromuscul Dis. 2025;12(2):231\u201343.","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"1335_CR19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/22143602241305511","volume":"12","author":"V Bril","year":"2025","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, et al. Rozanolixizumab in generalized myasthenia gravis: pooled analysis of the phase 3 MycarinG study and two open-label extensions. J Neuromuscul Dis. 2025;12(2):218\u201330.","journal-title":"J Neuromuscul Dis"},{"key":"1335_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/17562864261458532","author":"V Bril","year":"2026","unstructured":"Bril V, Druzdz A, Grosskreutz J, et al. Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions. Ther Adv Neurol Disord. 2026. https:\/\/doi.org\/10.1177\/17562864261458532.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"1335_CR21","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/mus.70014","volume":"72","author":"AA Habib","year":"2025","unstructured":"Habib AA, Dru\u017cd\u017c A, Lange D, et al. Repeated cycles of rozanolixizumab treatment in patients with anti-muscle-specific tyrosine kinase antibody-positive generalized myasthenia gravis [abstract no. 36 plus poster]. Muscle Nerve. 2025;72(4):678\u20131020.","journal-title":"Muscle Nerve"},{"issue":"4","key":"1335_CR22","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/mus.70014","volume":"72","author":"T Vu","year":"2025","unstructured":"Vu T, Habib AA, Sacconi S, et al. Rozanolixizumab treatment patterns in patients with generalized myasthenia gravis: a post hoc analysis of final pooled phase 3 data [abstract no. 85 plus poster]. Muscle Nerve. 2025;72(4):678\u20131020.","journal-title":"Muscle Nerve"},{"issue":"5","key":"1335_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383\u201394.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1335_CR24","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R, et al. Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve. 2022;65(6):630\u20139.","journal-title":"Muscle Nerve"},{"key":"1335_CR25","unstructured":"US Food & Drug Administration. Rozanolixizumab: integrated review. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761286Orig1s000TOC.html. Accessed 25 Aug 2026."},{"key":"1335_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17562864241273036","volume":"17","author":"AA Habib","year":"2024","unstructured":"Habib AA, Sacconi S, Antonini G, et al. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. Ther Adv Neurol Disord. 2024;17:1\u201316.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"1335_CR27","first-page":"612","volume":"70","author":"T Vu","year":"2024","unstructured":"Vu T, Habib AA, Pascuzzi RM, et al. Rozanolixizumab in patients aged \u226565 years with generalized myasthenia gravis: a post hoc analysis of the phase 3 MycarinG sudy [abstract no. 300]. Muscle Nerve. 2024;70(3):612\u20133.","journal-title":"Muscle Nerve"},{"issue":"1","key":"1335_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-066445","volume":"13","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Philips G, Paci S, et al. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ Open. 2023;13(1):e066445.","journal-title":"BMJ Open"},{"key":"1335_CR29","doi-asserted-by":"crossref","unstructured":"Kaminski HJ, Antozzi C, Habib AA, et al. Improvement in patient-reported symptoms of generalised myasthenia gravis with rozanolixizumab in the randomised phase 3 MycarinG study using the MG Symptoms PRO. Eur J Neurol. 2025;32(8):1\u201311.","DOI":"10.1111\/ene.70231"},{"key":"1335_CR30","doi-asserted-by":"crossref","unstructured":"Mahuwala ZK, Habib AA, Pascuzzi RM, et al. Effect of rozanolixizumab on ocular symptoms in patients with generalized myasthenia gravis: a post hoc item-level analysis of myasthenia gravis-specific outcomes in MycarinG [abstract no. P1-11.006]. Neurology. 2025;104(7 Suppl. 1):1866.","DOI":"10.1212\/WNL.0000000000208795"},{"issue":"2S","key":"1335_CR31","first-page":"S16","volume":"26","author":"T Wallace","year":"2025","unstructured":"Wallace T, Antozzi C, Grosskreutz J, et al. Effect of rozanolixizumab on bulbar and respiratory symptoms in patients with generalized myasthenia gravis: post hoc item-level [abstract plus poster]. J Clin Neuromuscul Dis. 2025;26(2S):S16.","journal-title":"J Clin Neuromuscul Dis"},{"key":"1335_CR32","unstructured":"European Medicines Agency. Rozanolixizumab (Rystiggo): EU assessment report. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rystiggo. Accessed 25 Aug 2026."},{"issue":"9","key":"1335_CR33","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s40265-025-02211-y","volume":"85","author":"S Fung","year":"2025","unstructured":"Fung S. Nipocalimab: first approval. Drugs. 2025;85(9):1185\u201392.","journal-title":"Drugs"},{"key":"1335_CR34","unstructured":"US Food & Drug Administration. VYVGART HYTRULO\u00ae (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use: US prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/761304Orig1s000TOC.html. Accessed 25 Aug 2026."},{"issue":"11","key":"1335_CR35","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s40265-024-02101-9","volume":"84","author":"HA Blair","year":"2024","unstructured":"Blair HA. Efgartigimod: a review in generalised myasthenia gravis. Drugs. 2024;84(11):1463\u201374.","journal-title":"Drugs"},{"issue":"10","key":"1335_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.538","volume":"6","author":"S Hoffmann","year":"2016","unstructured":"Hoffmann S, Ramm J, Grittner U, et al. Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav. 2016;6(10):e00538.","journal-title":"Brain Behav"},{"issue":"1","key":"1335_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s13023-021-02064-0","volume":"16","author":"S Cleanthous","year":"2021","unstructured":"Cleanthous S, Mork AC, Regnault A, et al. Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease. Orphanet J Rare Dis. 2021;16(1):457.","journal-title":"Orphanet J Rare Dis"},{"key":"1335_CR38","doi-asserted-by":"crossref","unstructured":"Regnault A, Morel T, de la Loge C, et al. Measuring overall severity of myasthenia gravis (MG): evidence for the added value of the MG Symptoms PRO. Neurol Ther. 2023;12(5):1573\u201390.","DOI":"10.1007\/s40120-023-00464-x"},{"key":"1335_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2024.1368525","volume":"15","author":"A Regnault","year":"2024","unstructured":"Regnault A, Habib AA, Creel K, et al. Clinical meaningfulness and psychometric robustness of the MG symptoms PRO scales in clinical trials in adults with myasthenia gravis. Front Neurol. 2024;15:1\u201314.","journal-title":"Front Neurol"},{"key":"1335_CR40","doi-asserted-by":"crossref","unstructured":"Pascuzzi RM, Antozzi C, Habib AA, et al. Correlation between MG Symptoms PRO and existing MG-specific outcome scores in the phase 3 MycarinG study: post hoc analysis [abstract no. P1\u201311.026]. Neurology. 2025;104(7 Suppl. 1):1865.","DOI":"10.1212\/WNL.0000000000208794"},{"key":"1335_CR41","unstructured":"US Food & Drug Administration. UPLIZNA\u00ae (inebilizumab-cdon) injection, for intravenous use: US prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/761142Orig1s000TOC.html. Accessed 25 Aug 2026."},{"key":"1335_CR42","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2147\/PPA.S303279","volume":"15","author":"PM Overton","year":"2021","unstructured":"Overton PM, Shalet N, Somers F, et al. Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adher. 2021;15:811\u201334.","journal-title":"Patient Prefer Adher"},{"issue":"9","key":"1335_CR43","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0171","volume":"13","author":"V Bril","year":"2024","unstructured":"Bril V, Lampe J, Cooper N, et al. Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis. J Comp Eff Res. 2024;13(9):e230171.","journal-title":"J Comp Eff Res."},{"issue":"4","key":"1335_CR44","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10875-018-0507-x","volume":"38","author":"B Bienvenu","year":"2018","unstructured":"Bienvenu B, Cozon G, Mataix Y, et al. Rapid push vs pump-infused subcutaneous immunoglobulin treatment: a randomized crossover study of quality of life in primary immunodeficiency patients. J Clin Immunol. 2018;38(4):503\u201312.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1335_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.anai.2013.04.015","volume":"111","author":"RS Shapiro","year":"2013","unstructured":"Shapiro RS. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol. 2013;111(1):51\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1335_CR46","unstructured":"Brandsema J, Kostera-Pruszczyk A, Addy I, et al. Subcutaneous rozanolixizumab in pediatric patients with generalized myasthenia gravis: clinical study design [abstract no. 204 plus poster]. In: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. 2023."},{"issue":"5","key":"1335_CR47","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","volume":"271","author":"J Li","year":"2024","unstructured":"Li J, Wu X, Chu T, et al. The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2024;271(5):2298\u2013308.","journal-title":"J Neurol"},{"key":"1335_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1479685","volume":"15","author":"HH Zhong","year":"2024","unstructured":"Zhong HH, Li ZJ, Li XC, et al. Initiation response, maximized therapeutic efficacy, and post-treatment effects of biological targeted therapies in myasthenia gravis: a systematic review and network meta-analysis. Front Neurol. 2024;15:11.","journal-title":"Front Neurol"},{"issue":"12","key":"1335_CR49","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1007\/s12325-024-03014-5","volume":"41","author":"AG Smith","year":"2024","unstructured":"Smith AG, Wolfe GI, Habib AA, et al. Risk-benefit analysis of novel treatments for patients with generalized myasthenia gravis. Adv Ther. 2024;41(12):4628\u201347.","journal-title":"Adv Ther"},{"issue":"3","key":"1335_CR50","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"414","key":"1335_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aan1208","volume":"9","author":"P Kiessling","year":"2017","unstructured":"Kiessling P, Lledo-Garcia R, Watanabe S, et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med. 2017;9(414):1\u201312.","journal-title":"Sci Transl Med"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01335-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01335-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01335-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:35:08Z","timestamp":1793277308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01335-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1335"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01335-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A. McGuigan and H. A. Blair are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}